Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing.
D001777:Blood Coagulation / Q000187:drug effects; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood / Q000276:immunology; D001779:Blood Coagulation Factors / Q000378:metabolism; D001792:Blood Platelets / Q000201:enzymology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005167:Factor VII / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D015942:Factor VIIa; D006467:Hemophilia A / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D002836:Hemophilia B / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006470:Hemorrhage / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007263:Infusions, Parenteral; D007267:Injections; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000097:blood / Q000276:immunology / Q000627:therapeutic use; D016896:Treatment Outcome
D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa